Cancer Immunotherapy Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 136.39 Bn

Forecast Year, 2035

USD 367.63 Bn

CAGR, 2026 - 2035

10.42%

Report Coverage

Global

What is the Cancer Immunotherapy Market Size?

The global cancer immunotherapy market size is valued at USD 136.39 billion in 2025 and is predicted to increase from USD 151.26 billion in 2026 to approximately USD 367.63 billion by 2035, expanding at a CAGR of 10.42% from 2026 to 2035. The rising number of approvals by regulatory agencies for novel immunotherapies is anticipated to further help the growth of cancer immunotherapy market.

Cancer Immunotherapy Market Key Takeaways

• The North American region has contributed 42.14% revenue share in 2025.
• The Asia Pacific market is expected to grow at the fastest CAGR over the forecast period.
• By products, the monoclonal antibodies segment has held a revenue share of over 71.51% in 2025.
• By distribution channel, the hospital pharmacy segment has held a revenue share of 58.2% in 2025.
• By end-use, the hospital segment has held the largest revenue share of 67% in 2025.

What is Cancer Immunotherapy?

Cancer immunotherapy drugs are specifically created for boosting or altering human's body's natural immune response to fight diseases. This therapy is completely driven by research and developments efforts. Innovations by researchers and investment in research and developments have contributed to growth of the cancer immunotherapy market. The rising number of people and medical professionals opting for immunotherapy is rising day by day, helping the expansion of this market. This therapy is becoming a popular choice because it is cost-effective and has considerably less side effects from the treatments. Most key players are focusing on research and development activities to come up with novel treatments to help patients with cancer. These factors will drive the growth of cancer immunotherapy market in the forecast period.

Artificial Intelligence (AI) in cancer immunotherapy

Artificial Intelligence (AI) can be big boost for the cancer immunotherapy market in the coming years. AI has different applications that will help with various process of cancer immunotherapy treatment. Generative AI can be used for the development of mRNA-based cancer vaccines that are personalized. With generative AI, the development of superior mRNA molecules by uncovering potential sequence patterns as well as structure is possible. These AI based models will be able to provide an effective strategy for the designing on mRNA. Another benefit of utilizing AI is speeding up the drug discovery process for cancer. AI and machine learning (ML) model can run through numerous variations and analyze combinations that match while eliminating the rest. This gives researchers an edge in development of drug discovery by speeding up the process. There is plenty of scope for AI applications in the cancer immunotherapy market.

Cancer Immunotherapy Market Growth Factors

• The global cancer immunotherapy market is primarily driven by the rising prevalence of cancer among the population and rising number of deaths associated with cancer disease. The global cancer cases are estimated to grow by 47% from 2020 to 2040.
• The traditional chemotherapy had certain disadvantages like organ failure and reoccurrence of cancer that drives the adoption of the new cancer immunotherapy among the patients.
• The technological advancements and development of new drugs has boosted the growth of the cancer immunotherapy market.
• The cancer immunotherapy directs the immune system to target the cancer affected cells and destroys the cancel cells. This therapy has less side effects and have long term treatment affects, which boosts the demand for the cancer immunotherapy across the globe.

Market Scope

Market Dynamics

Drivers

Rising cases of cancer

There is a noticeable increase in cases of cancer across the world. According to International Agency for Research on Cancer, in 2020, the number of cases were around 19.29 million and they estimate that in a decade by 2030, the number of cases will go up to 24.58 million. The change in lifestyle, rising ageing population combined with hereditary cancer cases rising are pushing the cancer cases up every passing year. This factor is a major driver for the cancer immunotherapy market and will continue to push market growth in the coming years.

Restraint

Clinical and Technological Challenges

Some clinical and technological challenges impose major limitations on the growth of the cancer immunotherapy market. Immune toxicities can develop side effects with severity ranging from autoimmune responses to cytokine storms, and therefore, patient monitoring and management require extreme care. Furthermore, while some patients even become resistant to immunotherapy, thus requiring combination therapies or alternative modes of therapy to sustain the treatment effect on the patient, these therapies themselves are steeply priced owing to complicated manufacturing procedures, especially of advanced therapies like cell-based therapies, such as CAR-T cell therapies , and logistics . Such hindrances have led to slow acceptance and use of immunotherapies, thus hindering the growth of the market.

Opportunity

Innovation

For this market, innovation is the key. It is only possible through research and development activities. The global cancer immune therapy market has already experienced a certain level of innovation and unique developments. The investments in research and development activities by key players have already made substantial progress with advancement in targeted therapies, customized treatments based on genetic profiles, precision medicine. These treatments offer different ways of helping patients fight cancer. In the forecast period, they key to further drive innovation is for major players to look for collaborations, acquisitions, partnerships etc. that can open up new avenues and geographical markets.

Cancer Immunotherapy Market Segment Insights

[[segment_insights]]

Cancer Immunotherapy Market Regional Insights

[[regional_insights]]

Value Chain Analysis of the Cancer Immunotherapy Market

• R&D: The discovery of tumor antigens and new modalities such as checkpoint inhibitors and CAR-T to improve the immune response.
  Key Players: Merck & Co., Bristol Myers Squibb, Roche (Genentech), AstraZeneca
• Clinical Trials and Regulatory Approvals: Safety and efficacy testing of patients, FDA and EMA market entry approvals.
  Key players: FDA (Regulatory), AstraZeneca, Merck, Roche
• Preparation of Formulation and Final Dosage: Revolutionizing active compounds into stable and bioavailable, patient-ready forms that demand intricate customized methods.
  Key players: Lonza, Catalent, WuXi Biologics, Thermo Fisher Scientific
• Packaging and Serialization: Using secure and trackable names on the packaging to comply with counterfeiting laws.
  Key players: Becton Dickinson, West Pharmaceutical Services, Gerresheimer
• Distribution to Hospitals, Pharmacies: Oversight of dedicated cold chain logistics that supply the care providers with high-value treatments in a secure manner.
  Key players: AmerisourceBergen (Cencora), Cardinal Health, McKesson

Cancer Immunotherapy MarketCompanies

• Amgen, Inc. : Amgen is designing bispecific T-cell engagers, oncolytic virus therapies, as well as next-generation T-cell therapies of hematologic and solid tumors.
• Astrazeneca, PLC : AstraZeneca develops immuno-oncology with PD-L1, CTLA-4, antibody-drug-conjugates, and combinations of regimens that boost immune responses.
• Bayer AG: Bayer specializes in targeted radionuclide therapy, precision oncology drugs, and antibody-drug conjugates for advanced solid tumors.
• Bristol-Myers Squibb Company: A leader in checkpoint inhibitors like Opdivo and Yervoy, now pivoting toward next-generation subcutaneous and cell therapies.
• Eli Lilly and Company: Focused on diversifying its oncology portfolio through strategic partnerships to develop programmable T-cell and TCR-based medicines.
• F. Hoffmann-La Roche, Ltd: Offers the PD-L1 inhibitor Tecentriq and is heavily investing in T-cell bispecific antibodies that link immune cells to tumors.
• Pfizer, Inc.: Utilizing its Seagen acquisition to combine antibody-drug conjugates with new immunotherapies like the bispecific antibody Elrexfio.
• Johnson & Johnson: Specializes in advanced CAR-T cell therapies such as Carvykti and the development of targeted immune-modulating peptides.
• Merck KGaA: Focuses on the anti-PD-L1 therapy Bavencio and exploring combination treatments that pair immunotherapy with targeted inhibitors.
• Novartis AG: A pioneer in CAR-T therapy with Kymriah, now advancing immune cell engagers for difficult-to-treat solid and liquid tumors.

Cancer Immunotherapy Market Segments Covered in the Report

[[segment_covered]]